Published in Metabolism on March 04, 2010
Divergence of intracellular and extracellular HSP72 in type 2 diabetes: does fat matter? Cell Stress Chaperones (2012) 0.96
Targeting protein homeostasis in sporadic inclusion body myositis. Sci Transl Med (2016) 0.88
Chaperoning to the metabolic party: The emerging therapeutic role of heat-shock proteins in obesity and type 2 diabetes. Mol Metab (2014) 0.88
Aging does not reduce heat shock protein 70 in the absence of chronic insulin resistance. J Gerontol A Biol Sci Med Sci (2012) 0.83
Immunohistochemical profiling of the heat shock response in obese non-diabetic subjects revealed impaired expression of heat shock proteins in the adipose tissue. Lipids Health Dis (2014) 0.79
Exercise, heat shock proteins and insulin resistance. Philos Trans R Soc Lond B Biol Sci (2018) 0.76
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Retracted Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA (2013) 4.88
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Breaking up prolonged sitting reduces postprandial glucose and insulin responses. Diabetes Care (2012) 4.50
Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med (2008) 4.25
Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes (2008) 4.13
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int (2011) 3.96
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int (2013) 3.42
Mechanisms of diabetic complications. Physiol Rev (2013) 3.41
Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med (2012) 3.31
Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab (2008) 3.00
A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res (2003) 2.69
Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J (2005) 2.66
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med (2014) 2.64
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
HSP72 protects against obesity-induced insulin resistance. Proc Natl Acad Sci U S A (2008) 2.52
Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes (2007) 2.51
Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes (2008) 2.41
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37
Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes (2009) 2.34
The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care (2003) 2.33
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24
Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol (2010) 2.22
Similar effects of treatment on central and brachial blood pressures in older hypertensive subjects in the Second Australian National Blood Pressure Trial. Hypertension (2007) 2.13
Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension (2003) 2.10
Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol (2011) 2.06
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension (2011) 2.05
High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation (2009) 2.00
miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression. Diabetes (2010) 1.95
Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol (2005) 1.95
Advanced glycation endproducts in food and their effects on health. Food Chem Toxicol (2013) 1.94
Brachial blood pressure but not carotid arterial waveforms predict cardiovascular events in elderly female hypertensives. Hypertension (2006) 1.90
Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol (2006) 1.88
E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes (2010) 1.85
NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation (2013) 1.78
Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. Circ Res (2012) 1.78
Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation (2007) 1.74
RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol (2009) 1.72
Retracted Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med (2006) 1.71
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. J Hypertens (2003) 1.70
Retracted Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. JAMA (2007) 1.69
The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). Med J Aust (2006) 1.68
Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. Diabetes (2004) 1.67
Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int (2011) 1.63
Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation. Hypertension (2005) 1.60
Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 1.59
Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol (2002) 1.58
Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol (2004) 1.58
Arterial stiffness and prediction of cardiovascular risk. J Hypertens (2002) 1.57
Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney Int (2010) 1.57
Retracted Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension (2005) 1.57
Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res (2003) 1.55
Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol (2009) 1.53
Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes (2004) 1.51
Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology (2002) 1.50
AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol (2007) 1.49
UKPDS and the legacy effect. N Engl J Med (2008) 1.49
TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. Clin Sci (Lond) (2012) 1.49
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. Clin Exp Nephrol (2006) 1.46
Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes. J Hypertens (2002) 1.45
Activation of the Renin-Angiotensin system mediates the effects of dietary salt intake on atherogenesis in the apolipoprotein E knockout mouse. Hypertension (2012) 1.43
Serum carboxymethyllysine concentrations are reduced in diabetic men with abdominal aortic aneurysms: Health In Men Study. J Vasc Surg (2009) 1.41
ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab (2004) 1.40
Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation (2009) 1.40
Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens (2005) 1.40
Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscler Thromb Vasc Biol (2011) 1.39
Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance. Diabetes (2012) 1.38
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis (2012) 1.38
Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation (2004) 1.38
Gender, sex hormones and autonomic nervous control of the cardiovascular system. Cardiovasc Res (2002) 1.38
ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes (2008) 1.36
Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes (2002) 1.36
Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol (2005) 1.35
The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J (2003) 1.33
Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol (2003) 1.32
The role of AGEs in cardiovascular disease. Curr Pharm Des (2008) 1.29
Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol (2004) 1.28